<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2658">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01508455</url>
  </required_header>
  <id_info>
    <org_study_id>DEX-11-06</org_study_id>
    <nct_id>NCT01508455</nct_id>
  </id_info>
  <brief_title>Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to &lt;36 Weeks Gestational Age</brief_title>
  <official_title>A Phase II/III, Open-Label, Multicenter, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to &lt;36 Weeks Gestational Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospira, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospira, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Guatemala: Ministry of Public Health and Social Assistance</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to characterize the safety, and efficacy of
      Dexmedetomidine (DEX) administered as an intravenous (IV) loading dose followed by a
      continuous IV infusion in preterm subjects, ages ≥ 28 weeks through &lt; 36 weeks gestational
      age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent of Subjects Requiring Rescue Midazolam for Sedation</measure>
    <time_frame>During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Rescue Medication (Fentanyl or Morphine) Use for Analgesia During DEX Infusion</measure>
    <time_frame>During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Rescue Medication (Midazolam) for Sedation During Dexmedetomidine Infusion</measure>
    <time_frame>During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Rescue Medication for Analgesia During DEX Infusion</measure>
    <time_frame>During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent With a Total N-PASS Score &gt;3 During DEX Infusion</measure>
    <time_frame>Predose, loading dose (LD) 5 &amp; 10mins/if LD is 20mins (5, 10, 15 &amp; 20mins); maintenance infusion: 0 min, every 15mins (1st hr); every 30mins (2hrs), then hourly; within 5mins of DEX discontinuation; 5mins pre and post rescue medication</time_frame>
    <safety_issue>No</safety_issue>
    <description>The N-PASS score &gt;3 indicates adequately sedated and not manifesting signs of pain/agitation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Successful Extubation</measure>
    <time_frame>From the start of study drug infusion to the study completion/withdrawal (Approximately 48 hours)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Initially intubated and mechanically ventilated pediatric subjects in an intensive
             care setting anticipated to require at least 6 hours of continuous IV sedation.

          2. Age: subjects must fit the following age range at screening:

             Preterm subjects ≥28 weeks through &lt;36 weeks, gestational age;

             Note: Gestational age (in weeks) will be calculated as follows: the time elapsed
             between the first day of the last menstrual period and the day of enrollment.

          3. Weight: subject's weight at the time of enrollment must be &gt;1000 g.

          4. Subject's parent(s) or legal guardian(s) has/have voluntarily signed and dated the
             informed consent document approved by the Institutional Review Board
             (IRB)/Independent Ethics Committee (IEC).

        Exclusion Criteria:

          1. Neonate subjects with neurological conditions that prohibit an evaluation of sedation
             such as:

               -  Diminished consciousness from increased intracranial pressure.

               -  The presence of catastrophic brain injury or other severe mental disorders that
                  would make responses to sedatives unpredictable and/or measurement of the N-PASS
                  unreliable.

               -  Subjects with immobility from neuromuscular disease or continuous infusion of
                  neuromuscular blocking (NMB) agents.

          2. Subjects with second degree or third degree heart block unless subject has a
             pacemaker or pacing wires are in situ.

             Note: If subject's status-post Cardio Pulmonary Bypass (CPB) was managed without
             pacing wires in situ, the subject must not be suspected to be in second degree or
             third degree heart block at the time of DEX administration.

          3. HR &lt; 120 bpm prior to the initiation of DEX.

          4. Exposure to any investigational drug within 30 days prior to DEX administration.

          5. Previous exposure to DEX as part of an investigational study.

          6. In subjects that are ex-utero for less than 72 hours, a maternal history of
             poly-substance drug abuse, based upon the Investigator's clinical judgment.

          7. At the discretion of the Investigator, subjects in whom the risk of DEX treatment is
             expected to exceed its benefits.

          8. Subjects who have a known allergy or contraindication to fentanyl, morphine, MDZ,
             DEX, or other α-2 agonists.

          9. Requirement for medications other than DEX, MDZ, morphine, or fentanyl for sedation
             and pain control.

         10. Screening ALT levels &gt;115 U/L.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>28 Weeks</minimum_age>
    <maximum_age>36 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 8, 2015</lastchanged_date>
  <firstreceived_date>January 5, 2012</firstreceived_date>
  <firstreceived_results_date>August 2, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Neonatal subjects enrolled from 3 centers in the United States</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dexmedetomidine</title>
          <description>Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects that received study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Dexmedetomidine</title>
          <description>Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <sub_title>Age Continuous</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0.8" spread="1.36"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Age Continuous: units: Gestational Age</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="32.5" spread="2.74"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Subjects Requiring Rescue Midazolam for Sedation</title>
        <time_frame>During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).</time_frame>
        <safety_issue>No</safety_issue>
        <population>All Subjects who received study drug for at least 6 hours</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Subjects Requiring Rescue Midazolam for Sedation</title>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Rescue Medication (Fentanyl or Morphine) Use for Analgesia During DEX Infusion</title>
        <time_frame>During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).</time_frame>
        <safety_issue>No</safety_issue>
        <population>All subjects who received DEX for at least 6 hours formed the Efficacy Evaluable Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence of Rescue Medication (Fentanyl or Morphine) Use for Analgesia During DEX Infusion</title>
            <units>participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Rescue Medication (Midazolam) for Sedation During Dexmedetomidine Infusion</title>
        <time_frame>During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).</time_frame>
        <safety_issue>No</safety_issue>
        <population>No participants analyzed for this assessment since none required rescue Midazolam for sedation.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Amount of Rescue Medication (Midazolam) for Sedation During Dexmedetomidine Infusion</title>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Rescue Medication for Analgesia During DEX Infusion</title>
        <time_frame>During the study drug administration (ie., loading dose 10 or 20 minutes and maintenance infusion minimum of 6 hours up to 24 hours) and during the post drug administration (up to 24 hours).</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number of subject who received rescue medication for analgesia during DEX infusion</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Amount of Rescue Medication for Analgesia During DEX Infusion</title>
            <units>mcg/kg</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent With a Total N-PASS Score &gt;3 During DEX Infusion</title>
        <description>The N-PASS score &gt;3 indicates adequately sedated and not manifesting signs of pain/agitation.</description>
        <time_frame>Predose, loading dose (LD) 5 &amp; 10mins/if LD is 20mins (5, 10, 15 &amp; 20mins); maintenance infusion: 0 min, every 15mins (1st hr); every 30mins (2hrs), then hourly; within 5mins of DEX discontinuation; 5mins pre and post rescue medication</time_frame>
        <safety_issue>No</safety_issue>
        <population>All subjects who received DEX for at least 6 hours formed the Efficacy Evaluable Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time Spent With a Total N-PASS Score &gt;3 During DEX Infusion</title>
            <description>The N-PASS score &gt;3 indicates adequately sedated and not manifesting signs of pain/agitation.</description>
            <units>Hours</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.44" spread="0.769"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Successful Extubation</title>
        <time_frame>From the start of study drug infusion to the study completion/withdrawal (Approximately 48 hours)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Subjects who had successful extubation alone (n=5) were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Successful Extubation</title>
            <units>Hours</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37.3" lower_limit="23.083" upper_limit="97.833"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment Emergent Adverse Events</time_frame>
      <desc>Treatment Emergent defined as start of study drug to 24 hours after discontinuation of study drug</desc>
      <group_list>
        <group group_id="E1">
          <title>Dexmedetomidine</title>
          <description>Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Umbilcal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypernatraenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Marcelo Garcia da Rocha</name_or_title>
      <organization>Hospira</organization>
      <phone>224-212-4424</phone>
      <email>marcelo.rocha@hospira.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
